（编辑 王雪儿） 证券日报网讯 新开源8月22日在互动平台回答投资者提问时表示，截至目前，公司的PVP产品尚未直接 向相关机器人企业供货，关于PVP在电子皮肤的应用，公司将持续透过其性能优势积极拓展下游潜在需 求。 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Xin Kai Yuan, which closed at 18.42 yuan with a PE ratio of 29.00, marking a new low in 297 days, and a total market capitalization of 8.953 billion yuan [1] - The chemical products industry has an average PE ratio of 50.34, with a median of 43.76, positioning Xin Kai Yuan at the 73rd rank within the industry [1] - The company experienced a net inflow of 43.83 million yuan in principal funds on August 22, with a total inflow of 4.0141 million yuan over the past five days [1] Group 2 - Xin Kai Yuan's main business focuses on fine chemicals and precision medicine, with key products including PVPK30, PVP-I, and various diagnostic services [1] - The latest financial results for Q1 2025 show a revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80.42 million yuan, down 33.75%, with a gross margin of 44.07% [1] - The PE ratios for Xin Kai Yuan are 29.00 (TTM) and 25.60 (static), with a price-to-book ratio of 2.41 [2]

天眼查商业履历信息显示，博爱新开源医疗科技集团股份有限公司，成立于2003年，位于焦作市，是一 家以从事医药制造业为主的企业。企业注册资本48605.0005万人民币，实缴资本48470.0005万人民币。 公司法定代表人为张军政。 通过天眼查大数据分析，博爱新开源医疗科技集团股份有限公司共对外投资了19家企业，参与招投标项 目34次，知识产权方面有商标信息56条，专利信息56条，此外企业还拥有行政许可95个。 来源：金融界 金融界消息 截至2025年8月22日收盘，新开源（300109）报收于18.42元，上涨1.49%，换手率4.69%， 成交量21.09万手，成交金额3.87亿元。 资金流向方面，今日主力资金净流入4383.46万元，占比成交额11.34%。其中，超大单净流入81.70万 元、占成交额0.21%，大单净流入4301.76万元、占成交额11.13%，中单净流出流出658.21万元、占成交 额1.7%，小单净流出3725.25万元、占成交额9.64%。 新开源最新一期业绩显示，截至2025一季报，公司营业总收入3.25亿元、同比减少17.69%，归属净利润 8042.03万元，同比减少33. ...

格隆汇8月22日丨新开源(300109.SZ)在投资者互动平台表示，截至目前，公司的PVP产品尚未直接向相 关机器人企业供货，关于PVP在电子皮肤的应用，公司将持续透过其性能优势积极拓展下游潜在需求。 ...

人民财讯8月22日电，新开源（300109）在互动平台上表示，截至目前，公司的PVP产品尚未直接向相 关机器人企业供货。关于PVP在电子皮肤的应用，公司将持续凭借其性能优势积极拓展下游潜在需求。 ...

Financial Performance - As of the closing on August 19, 2025, the company's stock price was 18.08 yuan, down 0.82% with a turnover rate of 3.76% and a trading volume of 169,100 hands, amounting to 305 million yuan in transaction value [1] - The latest quarterly report shows total revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit attributable to shareholders of 80.42 million yuan, down 33.75% year-on-year [1] - The company's non-recurring net profit was 69.42 million yuan, reflecting a year-on-year decrease of 44.85% [1] - The liquidity ratios are as follows: current ratio at 2.565, quick ratio at 2.016, and debt-to-asset ratio at 18.03% [1] Investment and Business Activities - The company has made investments in 19 enterprises and participated in 34 bidding projects [2] - It holds 56 trademark registrations and 56 patent registrations, along with 95 administrative licenses [2] Company Background - Founded in 2003, the company is based in Jiaozuo City and primarily engages in the pharmaceutical manufacturing industry [1] - The registered capital is approximately 4.86 billion yuan, with paid-in capital of about 4.85 billion yuan [1]

8月12日，新开源大宗交易成交55万股，成交额778.25万元，占当日总成交额的4.18%，成交价14.15元，较市场收盘价17.41 元折价18.72%。 | 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-08-12 | 300109 | 新开源 | 14.15 | 55.00 | 778.25 | 中国中金财富证券 | 中国银河证券股份 | | | | | | | | 有限公司杭州教工 | 有限公司北京苏州 | | | | | | | | 路证券营业部 | 街证券营业部 | ...

Group 1 - The article highlights a revolutionary breakthrough in genome editing technology, specifically a new programmable technique for precise manipulation of large DNA segments at the chromosomal level, which can edit DNA from thousands to millions of base pairs [1] - This new technology significantly enhances the scale and capability of manipulating eukaryotic genomes, providing new pathways for crop trait improvement and treatment of genetic diseases [1] - In the field of genetic disease treatment, this technology is expected to offer new therapeutic approaches for diseases caused by chromosomal abnormalities [1] Group 2 - The breakthrough in precise chromosomal editing technology is anticipated to accelerate the construction of artificial chromosomes, presenting important application prospects in emerging fields such as synthetic biology [1] - Relevant concept stocks in the A-share market include Xin Kai Yuan and Bei Rui Ji Yan, which are associated with this new technology [1]

资金方面，新开源8月11日主力资金净流出189.20万元，近五日累计净流出7159.22万元。 截至2025年8月11日15时8分，新开源股价报17.65元，较前一交易日上涨1.73%。当日开盘价为17.44 元，最高触及17.97元，最低下探17.36元，成交额达2.97亿元。 新开源主营业务涉及化学制品、CAR-T细胞疗法、固态电池等领域。公司所属板块包括河南板块、消毒 剂等概念。 消息面上，百川智能8月11日发布开源医疗增强大模型Baichuan-M2，在医疗能力上超越OpenAI最新开 源模型。该消息可能对医疗科技相关企业带来一定影响。 来源:金融界 风险提示：股市有风险，投资需谨慎。 ...

虽然不是我们期待已久的 GPT-5，但也是「something big-but-small today.」 终于，OpenAI 的新发布还是来了。 也就是开源新语言模型。 要知道，这是近几年来（自 GPT-2 以来），OpenAI 重新开源模型。 据在 OpenAI 任职研究科学家的清华校友翁家翌透露，从 2022 年 OpenAI 内部就讨论模型开源，并曾数次接近「开源」目的，但直到今天才实现。 这次还一下开源了两个，都是推理模型。 GitHub 地址：https://github.com/openai/gpt-osshugging face 地址：https://huggingface.co/openai/gpt-oss-20bhugging face 地址： https://huggingface.co/openai/gpt-oss-120b博客地址：https://openai.com/index/introducing-gpt-oss/ Sam Altman 声称，gpt-oss 性能与 o4-mini 水平相当，并且可以在高端笔记本电脑上运行（WTF！！）（还有一个较小的可以在手机上运行）。 宽松 ...